targetsTarget

Erythropoietin receptor (EPOR)

The receptor that tells the marrow to make red blood cells. Epoetin stimulates it to treat chemotherapy-induced anaemia, used with care because it can raise the risk of blood clots and, in some cancers, tumour growth.

Erythropoietin from the kidney binds EPOR on erythroid progenitors and signals through JAK2 and STAT5 to drive red cell production. Recombinant epoetin alfa and darbepoetin alfa raise haemoglobin and reduce transfusions in patients with chemotherapy-induced anaemia, but trials showed shorter survival and more thromboembolism when they were used to target normal haemoglobin levels or given outside chemotherapy, leading to restricted labels and a risk management programme in the United States. They are now used at the lowest dose that avoids transfusion, in patients on palliative-intent chemotherapy.

Erythropoietin receptor (EPOR): what it is and how drugs act on it · animated generic schematic, not to scale

Target · the protein and the cell it sits on
Drug · antibody, small molecule, cell or radioligand
Effect · signal, damage or kill

In plain words · The receptor that tells the marrow to make red blood cells. Epoetin stimulates it to treat chemotherapy-induced anaemia, used with care because it can raise the risk of blood clots and, in some cancers, tumour growth.

1 · What it is
The receptor that tells the marrow to make red blood cells. Epoetin stimulates it to treat chemotherapy-induced anaemia, used with care because it can raise the risk of blood clots and, in some cancers, tumour growth.
2 · What goes wrong in cancer
Cytokine receptor on erythroid progenitors signalling through JAK2 and STAT5; agonised by recombinant erythropoiesis-stimulating agents.
3 · How drugs use it
No product in this corpus aims at Erythropoietin receptor (EPOR) yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.